Sonoma pharmaceuticals reports third fiscal quarter 2024 financial results

Revenues increased 7% compared to quarter from prior year and 15% from prior quarter improvement in gross margin for quarter of 19% compared to prior year improvement in net loss for quarter of $1.0 million compared to prior year boulder, co / accesswire / february 8, 2024 / sonoma pharmaceuticals, inc. (nasdaq:snoa),a global healthcare leader developing and producing stabilized hypochlorous acid (hocl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for its third fiscal quarter and nine months ended december 31, 2023. "we are pleased to report increased revenues in the quarter ended december 31, 2023, both year over year and compared to the prior quarter," said amy trombly, ceo of sonoma.
SNOA Ratings Summary
SNOA Quant Ranking